^
Association details:
| Biomarker: | EGFR G465R |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | futuximab/modotuximab (S95026) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
Excerpt:
...a patient with a tumor harboring an EGFR mutation (G465R) following cetuximab therapy benefited from Sym004 therapy.
DOI:
10.1158/1078-0432.CCR-15-2400
